NPX372 immunotherapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (lung, kidney, colon, pancreas, bile duct, stomach, or ovarian cancer) that has come back or spread and didn't respond to standard treatments.
- Your cancer can be measured on imaging scans (RECIST criteria).
- You are at least 19 years old.
- Your kidney, liver, and blood cell function are adequate (specific lab values required).
- You have cancer tissue available from a previous biopsy, or are willing to have a new biopsy during screening.
- You are willing to use effective contraception for the duration of the trial plus 60 days after treatment ends (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called NPX887 that targets a protein (B7-H7) on certain cancer cells to help your immune system fight them. It is for people with advanced solid tumors that have not responded to other treatments.
This trial tests a new drug called PYX-201 combined with an immunotherapy (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help people live longer with manageable side effects.
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
This trial tests a new drug called SPX-303, which is designed to help your immune system fight cancer cells. It is for people with advanced solid tumors that have not responded to other treatments.
This trial tests a new drug called CX-5461 (also known as pidnarulex) in people whose cancer has spread and hasn't been helped by standard treatments. It looks at how your body responds to the drug, which may target cancers with specific DNA repair problems.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Hear when a new Metastatic Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.